Answers are grounded in this paper and cite their sources.
Type 2 diabetes is associated with insulin resistance (IR). IR is partially caused by the cytokine tumor necrosis factor-α (TNF-α), which is produced in inflammatory fat tissue in muscle, liver, and adipose tissue. Inflamed abdominal fat releases adipokines and inflammatory cytokines, one of which is TNF-α. Past experimental studies using anti–TNF-α therapy in type 2 diabetic patients have been limited in both time and dosage because of the toxicity of these agents. We designed a retrospective study in which anti–TNF-α agents were used in larger therapeutic doses for up to 10 years in patients with rheumatoid arthritis (RA) and Crohn's disease (CR). We assessed the effects of this treatment on control of type 2 diabetes. Eight Veterans Affairs patients with RA or CR and type 2 diabetes and a matched group of control patients with both …
No takes yet. Share an insight, caveat, or question.
Gupta-Ganguli et al. (2011) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: